The feasibility of adjuvant interferon α-2b in children with high-risk melanoma

Cancer

Volumn 103, Issue 4, 2005, Pages 780-787

  Navid, Fariba ^a   Furman, Wayne L ^a   Fleming, Martin ^b   Rao, Bhaskar N ^a   Kovach, Sandra ^a   Billups, Catherine A ^a   Cain, Alvida M ^a   Amonette, Rex ^b   Jenkins, Jesse J ^a   Pappo, Alberto S ^c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Children; Interferon 2b; Lymph node disease; Melanoma; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON;

ABDOMINAL PAIN; ADOLESCENT; AGITATION; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHILL; CLINICAL ARTICLE; CONSCIOUSNESS DISORDER; CONSTIPATION; DEHYDRATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERHIDROSIS; HYPERTENSION; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; LEUKOPENIA; LIVER DYSFUNCTION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAINTENANCE THERAPY; MALE; MELANOMA; METABOLIC DISORDER; MYALGIA; NEUROTOXICITY; NEUTROPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RASH; SCHOOL CHILD; SENTINEL LYMPH NODE BIOPSY; SIDE EFFECT; SINUS TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION; WOUND INFECTION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; FEASIBILITY STUDIES; HUMANS; INFANT; INTERFERON ALFA-2B; LYMPH NODE EXCISION; MELANOMA; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL;

EID: 13444300931     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20860     Document Type: Article

References (33)

1. U.S. Cancer Statistics Working Group. United States cancer statistics: 2000 incidence. Atlanta: Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, 2003.
2. Ries LG, Smith M, Gurney J, Linet M, Tmara T, Young JL. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda: National Cancer Institute, 1999.
3. Schmid-Wendtner MH, Berking C, Baumert J, et al. Cutaneous melanoma in childhood and adolescence: an analysis of 36 patients. J Am Acad Dermatol. 2002;46:874-879.
4. Gibbs P, Moore A, Robinson W, Walsh P, Golitz L, Gonzalez R. Pediatric melanoma: are recent advances in the management of adult melanoma relevant to the pediatric population. J Pediatr Hematol Oncol. 2000;22:428-432.
5. Hamre MR, Chuba P, Bakhshi S, Thomas R, Severson RK. Cutaneous melanoma in childhood and adolescence. Pediatr Hematol Oncol. 2002;19:309-317.
6. Gelbard SN, Tripp JM, Marghoob AA, et al. Management of Spitz nevi: a survey of dermatologists in the United States. J Am Acad Dermatol. 2002;47:224-230.
7. Barnhill RL, Argenyi ZB, From L, et al. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol. 1999;30:513-520.
8. Saenz NC, Saenz-Badillos J, Busam K, LaQuaglia MP, Corbally M, Brady MS. Childhood melanoma survival. Cancer. 1999;85:750-754.
9. Williams ML, Pennella R. Melanoma, melanocytic nevi, and other melanoma risk factors in children. J Pediatr. 1994;124: 833-845.
10. Pappo AS. Melanoma in children and adolescents. Eur J Cancer. 2003;39:2651-2661.
11. Pappo AS, Ries L, Herzog C, Bleyer A. Malignant melanoma in the first three decades of life: a report from the U.S. Surveillance, Epidemiology, and End Results (SEER) Program. Proc Am Soc Clin Oncol, 2004;22:724S.
12. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (Stage II). Ann Surg. 1981;193:377-388.
13. Balch CM, Murad TM, Soong SJ, Ingalls AL, Halpern NB, Maddox WA. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg. 1978;188:732-742.
14. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.
15. Milton GW, Shaw HM, Thompson JF, McCarthy WH. Cutaneous melanoma in childhood: incidence and prognosis. Australas J Dermatol. 1997;38(Suppl 1):S44-S48.
16. Rao BN, Hayes FA, Pratt CB, et al. Malignant melanoma in children: its management and prognosis. J Pediatr Surg. 1990;25:198-203.
17. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7-17.
18. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670-1677.
19. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected Stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001; 19:2370-2380.
20. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18:2444-2458.
21. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ. Malignant melanoma of the skin (excluding eyelid). In: Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, eds. AJCC manual for staging of cancer, 4th ed. Philadelphia: JB Lippincott Company, 1992:143-145.
22. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol. 2002;20:1818-1825.
23. Sabel MS, Sondak VK. Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist 2003;8:451-458.
24. Spatz A, Ruiter D, Hardmeier T, et al. Melanoma in childhood: an EORTC-MCG multicenter study on the clinicopathological aspects. Int J Cancer. 1996;68:317-324.
25. Lohmann CM, Coit DG, Brady MS, Berwick M, Busam KJ. Sentinel lymph node biopsy in patients with diagnostically controversial spitzoid melanocytic tumors. Am J Surg Pathol. 2002;26:47-55.
26. Su LD, Fullen DR, Sondak VK, Johnson TM, Lowe L. Sentinel lymph node biopsy for patients with problematic spitzoid melanocytic lesions: a report on 18 patients. Cancer. 2003; 97:499-507.
27. Smith KJ, Barren TL, Skelton HG 3rd, Lupton GP, Graham JH. Spindle cell and epithelioid cell nevi with atypia and metastasis (malignant Spitz nevus). Am J Surg Pathol. 1989; 13:931-939.
28. Mehregan AH, Mehregan DA. Malignant melanoma in childhood. Cancer. 1993;71:4096-4103.
29. Tate PS, Ronan SG, Feucht KA, Eng AM, Das Gupta TK. Melanoma in childhood and adolescence: clinical and pathological features of 48 cases. J Pediatr Surg. 1993;28: 217-2122.
30. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol, 2001;19:3635-3648.
31. Kogut KA, Fleming M, Pappo AS, Schropp KP. Sentinel lymph node biopsy for melanoma in young children. J Pediatr Surg. 2000;35:965-966.
32. Zuckerman R, Maier JP, Guiney WB Jr., Huntsman WT, Mooney EK. Pediatric melanoma: confirming the diagnosis with sentinel node biopsy. Ann Plast Surg. 2001;46:394-399.
33. Toro J, Ranieri JM, Havlik RJ, Coleman JJ 3rd, Wagner JD. Sentinel lymph node biopsy in children and adolescents with malignant melanoma. J Pediatr Surg. 2003;38:1063-1065.